Omnicell, Inc. (OMCL) Earnings

Management highlights

- Organizational Update • Nnamdi Njoku was promoted to President and Chief Operating Officer on July 1, 2026 to accelerate company-wide execution; no changes to CEO Randall Lipps' role or the company's core strategy, and the promotion reinforces management's focus on execution and long-term stakeholder value. • Nnamdi's core priorities include scaling operations, driving P&L operating leverage, aligning enterprise product strategy and customer engagement, and advancing the innovation roadmap for sustained long-term growth. - Industry and Demand Dynamics • Health system customers continue to prioritize investments that improve operational efficiency, address staff shortages and cost pressures, with Omnicell's solutions increasingly viewed as strategic, enterprise-wide platforms. • Pipeline activity for Omnisphere and Titan XT solutions has grown meaningfully, as customers focus on enterprise-wide medication visibility, interoperability, workflow transformation, and operational efficiency. This is the first product refresh cycle where both Omnicell and its largest competitor have launched new platforms simultaneously, leading to more and larger competitive conversion opportunities with longer sales cycles due to broad stakeholder evaluations. • Expanded leasing programs leveraging Omnicell's balance sheet support attractive economics for both customers and the business, and act as a competitive differentiator for large enterprise deals. - Product and Operational Milestones • Titan XT automated dispensing system remains on track for general shipment in H2 2026; Omnisphere ADS remains on track for general availability in H1 2027. • Secured the first competitive Titan XT conversion win of 2026 with a Southeast U.S. health system, which also selected multiple additional Omnicell solutions as part of a broader medication management transformation. Secured additional Titan XT wins from three existing customers, including two academic medical centers. • Achieved meaningful momentum in specialty pharmacy, including a competitive greenfield win with the largest healthcare provider in Northwest Arizona, and opened two new specialty pharmacy engagements with Oregon and Missouri-based health systems, expanding the segment's footprint. • Omnisphere is positioned as the cloud-native unifying platform to connect all Omnicell devices, data, and workflows, enabling guided, increasingly autonomous medication management with integrated AI and analytics capabilities.

Guidance

- Third Quarter 2026 Guidance: • Total revenue expected in the range of $301 million to $307 million; product revenue expected $169 million to $172 million; service revenue expected $132 million to $135 million. • Non-GAAP EBITDA expected $32 million to $37 million; non-GAAP earnings per share expected $0.35 to $0.43, with the sequential decline reflecting the absence of Q2's one-time $15 million tariff refund, lower expected revenue, lower gross margins, and higher operating expenses partially offset by ongoing cost discipline. - Full Year 2026 Guidance Updates: • Product bookings guidance updated to a wide range of $425 million to $560 million: the upper end remains unchanged from prior guidance (reflecting current pipeline transactions that could close in 2026), while the lower end was materially lowered to reflect uncertainty around the timing of large/medium enterprise purchasing decisions, not a deterioration in underlying demand. • Total revenue guidance set to $1.225 billion to $1.245 billion; product revenue expected $690 million to $700 million; service revenue expected $535 million to $545 million. • Year-end 2026 ARR guidance revised to $660 million to $680 million, with the adjustment primarily reflecting timing delays for certain consumables business growth opportunities, not lower demand. • Full year 2026 Non-GAAP EBITDA guidance raised to $175 million to $185 million; non-GAAP earnings per share guidance raised to $2.15 to $2.30, reflecting the benefit of the Q2 tariff refund and improved operating discipline/leverage across the business.

Segment performance

Omnicell reports two core product segments for Q2 2026: 1. Product Segment: Total product revenue was $175 million, accounting for 56.1% of total Q2 2026 revenue of $312 million. Performance reflected steady demand for connected devices across both North American and international markets. 2. Service Segment: Total service revenue was $137 million, accounting for 43.9% of total Q2 2026 revenue. Growth was driven by strong performance across recurring revenue streams, including specialty pharmacy services, maintenance, support, and software-related offerings.

Risks & headwinds

- Extended sales cycle timelines for large enterprise competitive deals introduce meaningful variability to 2026 product bookings, as multi-stakeholder evaluations and multi-quarter to multi-year capital approval processes make near-term forecasting uncertain. • An imbalanced global supply and demand environment for memory chips is expected to add $6 million in incremental costs to H2 2026, representing a 50 basis point hit to full year consolidated gross margin and an 80 basis point hit to full year product gross margin. • The current installed base of legacy XT systems is younger than the G-series installed base was at the time of the G-series to XT transition, leading to earlier engagement for the current refresh cycle and pushing some purchasing decisions out past 2026. • Forward-looking statements around future performance and product adoption are subject to inherent risks and uncertainties that could cause actual results to differ materially from current expectations, as detailed in Omnicell's SEC filings.

Analyst Q&A

• Q: Why is the updated 2026 product bookings guidance range extremely wide, with the top end unchanged but the bottom end materially lowered? Are there material cancellations of legacy XT business, and what supports confidence in the top end of the range?

  A: Management kept the top end unchanged because it has clear line of sight to existing pipeline transactions that can reasonably close by the end of 2026. The wider range and lower bottom end reflect uncertainty around the timing of medium-sized and large deals during the first year of the Titan XT refresh cycle, not cancellations or lower demand. Omnicell's total exiting Q2 pipeline is larger than it has been in recent years, with strong customer engagement, so management chose to be transparent about the full range of possible 2026 outcomes.

• Q: What percentage of upcoming VECTRA renewal opportunities are going through a full competitive bidding process, and what is Omnisphere's finalized pricing model?

  A: Management stated the competitive process is still early, with a high volume of activity but no available exact percentage of competitive opportunities. It confirmed the pipeline is larger than ever and customer feedback on Titan XT and Omnisphere's enterprise visibility capabilities is positive. Omnisphere is on track for H1 2027 general availability, and management will share full details on its pricing, go-to-market, and revenue recognition model ahead of 2027 guidance.

• Q: Does the larger pipeline reflect more accounts, larger accounts, or both? What share of product bookings do you expect to come from leasing, and what determines when you offer leasing?

  A: The larger pipeline is a combination of early engagement with Omnicell's own XT install base and a higher volume of competitive conversations than in past cycles, as this is the first time both major market players have launched new platforms at the same time. For leasing, management notes it appeals to a subset of customers that prefer to spread payments aligned with cash flow needs. Leasing keeps customers in conversations longer and allows more time to showcase Omnicell's innovation, so it is expected to remain a relatively muted but valuable part of the go-to-market mix.

• Q: Are the delayed large enterprise bookings primarily existing Omnicell customers pushing Titan XT purchases to 2027, or competitive evaluations that are taking longer?

  A: The pipeline includes both large and medium-sized accounts. Existing XT customers, which are in the 10th year of the XT product cycle, are starting the transition process naturally, with some ready to move to Titan XT in 2026 and others starting conversations early that will close later. There is also heightened interest from competitive customer accounts, where Omnicell's innovation, reliability, and service standards have put the company in consideration for large conversion opportunities that are progressing through extended evaluations.